- Home
- NXP vs ADPT Comparison
NXP vs ADPT Comparison
Compare NXP & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXP
- ADPT
- Stock Information
- Founded
- NXP 1992
- ADPT 2009
- Country
- NXP United States
- ADPT United States
- Employees
- NXP N/A
- ADPT 709
- Industry
- NXP Trusts Except Educational Religious and Charitable
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NXP Finance
- ADPT Health Care
- Exchange
- NXP Nasdaq
- ADPT Nasdaq
- Market Cap
- NXP 715.7M
- ADPT 749.7M
- IPO Year
- NXP N/A
- ADPT 2019
- Fundamental
- Price
- NXP $14.55
- ADPT $5.08
- Analyst Decision
- NXP
- ADPT Buy
- Analyst Count
- NXP 0
- ADPT 4
- Target Price
- NXP N/A
- ADPT $6.50
- AVG Volume (30 Days)
- NXP 70.0K
- ADPT 1.1M
- Earning Date
- NXP 01-01-0001
- ADPT 11-07-2024
- Dividend Yield
- NXP 4.04%
- ADPT N/A
- EPS Growth
- NXP N/A
- ADPT N/A
- EPS
- NXP 0.54
- ADPT N/A
- Revenue
- NXP N/A
- ADPT $177,282,000.00
- Revenue This Year
- NXP N/A
- ADPT $3.82
- Revenue Next Year
- NXP N/A
- ADPT $20.38
- P/E Ratio
- NXP $26.81
- ADPT N/A
- Revenue Growth
- NXP N/A
- ADPT N/A
- 52 Week Low
- NXP $12.91
- ADPT $2.28
- 52 Week High
- NXP $14.89
- ADPT $6.70
- Technical
- Relative Strength Index (RSI)
- NXP 36.80
- ADPT 47.04
- Support Level
- NXP $14.55
- ADPT $5.09
- Resistance Level
- NXP $14.77
- ADPT $6.70
- Average True Range (ATR)
- NXP 0.16
- ADPT 0.46
- MACD
- NXP -0.01
- ADPT 0.00
- Stochastic Oscillator
- NXP 4.35
- ADPT 24.48
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a diversified closed-end investment company. It seeks to provide current income and stable dividends, exempt from regular federal and designated state income taxes, consistent with the preservation of capital by investing primarily in a portfolio of municipal obligations.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).